Conference report: Oncology pharmacoeconomics The Seventh International Symposium on Oncology Pharmacy Practice,Prague,Czech Republic,April 5-8,2000

Beltz SE , Yee GC. Pharmacoeconomics of cancer therapy. Cancer Control. 1998;5:415-424.

Greenberg PE , Arcelus A , Birnbaum HG , et al. Pharmacoeconomics and health policy. Current applications and prospects for the future. Pharmacoeconomics. 1999;16 (5 pt 1):425-432.

Leung PP , Tannock IF , Oza AM , Puodziunas A , Dranitsaris G. Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer. J Clin Oncol. 1999;17:3082-3090.

Jolicoeur LM , Jones-Grizzle AJ , Boyer JG. Guidelines for performing a pharmacoeconomic analysis. Am J Hosp Pharm. 1992;49:1741-1747.

Sanchez LA. Evaluating the quality of published pharmacoeconomic evaluations. Hosp Pharm. 1995;30:146-152.

Siegel JE , Weinstein MC , Russell LB , Gold MR. Recommendations for reporting cost effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276:1339-1341.

Heyland DK , Kernerman P , Gafni A , Cook DJ. Economic evaluations in the critical care literature: do they help us improve the efficiency of our unit? Crit Care Med. 1996;24:1591-1598.

Cancer Care Ontario Program in Evidence-Based Care (PEBC) and the Cancer Care Ontario Practice Guidelines Initiative (CCOPGI). Available at:http://hiru.mcmaster.ca/ccopgi/